Important Notice to Long-Term Shareholders of CorMedix Inc. (NASDAQ: CRMD); Maison Solutions, Inc. (NASDAQ: MSS); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating…
PHILADELPHIA, July 09, 2025 (GLOBE NEWSWIRE) --
CorMedix Inc. (NASDAQ: CRMD) Shareholder Class Action Survives Motion to Dismiss:
Current CorMedix Inc. (NASDAQ: CRMD) shareholders who have held CorMedix shares since prior to October 16, 2019, can now seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/cormedix-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
Why? As alleged in an underlying securities fraud class action complaint, Cormedix (NASDAQ: CRMD), via certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made material misrepresentations concerning the following: (i) deficiencies existed with respect to DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the FDA was unlikely to approve the DefenCath NDA for CRBSIs in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
On June 30, 2025, the court denied Defendants’ motion to dismiss the complaint, determining that Plaintiffs had adequately alleged material misrepresentations; scienter (either (1) a motive and opportunity to commit fraud or (2) "circumstantial evidence of either reckless or conscious behavior”); and loss causation.
What You Can Do Now: Current CorMedix shareholders who have held CorMedix shares since prior to October 16, 2019, can now seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/cormedix-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. #CorMedix $CRMD
Maison Solutions Inc. (NASDAQ: MSS) Class Action Survives Motion to Dismiss:
Grabar Law Office is investigating claims on behalf of shareholders of Maison Solutions Inc. (NASDAQ: MSS) as an underlying securities fraud class action has survived a motion to dismiss the complaint.
If you are a current Maison Solutions Inc. (NASDAQ: MSS) shareholder who purchased Maison shares on or near its October 5, 2023 IPO, you can seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/maison-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or call us at 267-507-6085
WHY? An underlying securities fraud class action complaint alleges that in Maison Solutions Inc.’s (NASDAQ: MSS) IPO Registration Statement and throughout the Class Period (October 5, 2023 through December 15, 2023), Maison, through certain of its officers, made materially false and/or misleading statements, including failing to disclose to investors: (1) that the Company’s vendor XHJC Holdings Inc., is a related party; (2) that the Company’s CEO and related entities were alleged to have used supermarkets as a front to defraud the EB-5 visa program; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On March 31, 2025, material portions of the underlying securities fraud complaint survived a motion to dismiss.
WHAT YOU CAN DO NOW: If you purchased Maison Solutions Inc. (NASDAQ: MSS) shares on or near its October 5, 2023 IPO and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/maison-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You may be able to seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $MSS #MaisonSolutions
Napco Security Technologies, Inc. (NASDAQ: NSSC) Shareholder Class Action Survives Motion to Dismiss:
If you are a Current Napco Security Technologies, Inc. (NASDAQ: NSSC) shareholder who has held Napco shares since prior to November 7, 2022, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Click here to join or learn more: https://grabarlaw.com/the-latest/Napco-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
Why? Key allegations in a recently filed securities fraud class action complaint against the company and certain of its officers have survived a motion to dismiss. That complaint alleges that Napco Security Technologies, Inc. (NASDAQ: NSSC), through certain of its officers and directors, made materially false and/or misleading statements and/or failed to disclose that: (1) Napco failed to address any material weaknesses with internal controls regarding cost of goods sold ("COGS") and inventory; (2) Napco downplayed the severity of material weaknesses regarding their internal controls; (3) Napco’s unaudited financial statements from September 30, 2022 to the present included “certain errors” such as overstating inventory and understanding net COGS, resulting in overstated gross profit, operating income and net income for each period; (4) as a result, Napco would need to restate its previously filed unaudited financial statements for certain periods; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On April 11, 2025, the federal court determined that key allegations would survive Defendants’ motion to dismiss the complaint. In so holding, the court determined “Plaintiffs have adequately stated Exchange Act claims by pleading scienter [knowledge of wrongdoing] through defendants’ unusual stock sales and by plausibly alleging loss causation between the corrective announcement and stock price drop. Plaintiffs have also stated Securities Act claims against Napco and the underwriter defendants.” . . . “Taking the well-pleaded facts as true, there is no question that plaintiffs have adequately pled scienter. First, the stock sales were highly unusual in timing and amount. As to amount, the total proceeds of over $108 million from stock sales by the officer defendants weigh in favor of a motive. . . . And the officer defendants sold hefty percentages of their holdings – 48.5% for Soloway and 45.5% for Buchel.”
What To Do Now: If you have held Napco shares since before November 7, 2022 and would like to learn more about this matter, please visit https://grabarlaw.com/the-latest/Napco-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $NSSC #NAPCO
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
If you have held Treace Medical Concepts (NASDAQ: TMCI) shares continuously since prior to May 8, 2023, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit https://grabarlaw.com/the-latest/treace-shareholder-investigation/, or contact Joshua H. Grabar at jgrabar@grabarlaw.com or call 267-507-6085 to learn more.
Why? A recently filed securities class action complaint alleges that, Treace Medical Concepts, Inc. (NASDAQ: TMCI), via certain of its officers, made materially false and/or misleading statements and failed to disclose adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System; (2) as a result, Treace Medical’s revenue declined, and the Company needed to accelerate its plans to offer a product that served as an alternative to osteotomy (a surgical procedure involving the cutting and realignment of a bone to improve its position or function); and (3) Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What You Can Do Now: Current Treace shareholders who have held Treace shares since prior to May 8, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/treace-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085. #Treace $TMCI
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
